TABLE 2.
Antibiotic treatment regimensa
| Antibiotic | Value(s) for patients with the following infection: |
||
|---|---|---|---|
| MABC (n = 48) | MAC (n = 20) | Mixed (n = 9) | |
| No. (%) of patients receiving the following before amikacin inhalation therapy: | |||
| Macrolide | 48 (100) | 20 (100) | 9 (100) |
| Ethambutol | 0 | 20 (100) | 8 (89) |
| Rifampin | 0 | 20 (100) | 8 (89) |
| Clofazimine | 33 (69) | 5 (25) | 7 (78) |
| Moxifloxacin | 19 (40) | 12 (60) | 3 (33) |
| Imipenem | 34 (71) | 0 (0) | 8 (89) |
| Cefoxitin | 14 (29) | 0 (0) | 1 (11) |
| Amikacin or streptomycin injection | 48 (100) | 15 (75) | 5 (56) |
| Median (IQR) total treatment duration (mo) | 39.5 (15.8–84.2) | 38.5 (14.8–50.4) | 25.9 (17.5–47.1) |
| No. (%) of patients receiving the following after amikacin inhalation therapy: | |||
| Macrolide | 48 (100) | 20 (100) | 9 (100) |
| Ethambutol | 0 | 18 (90) | 8 (89) |
| Rifampin | 0 | 13 (65) | 4 (44) |
| Clofazimine | 43 (90) | 16 (80) | 8 (89) |
| Moxifloxacin | 0 | 1 (8) | 1 (11) |
| Amikacin inhalation | 48 (100) | 20 (100) | 9 (100) |
| Median (IQR) duration of amikacin inhalation therapy (mo) | 12.0 (6.8–12.0) | 12.0 (5.3–12.0) | 12.0 (12.0–12.0) |
a
Abbreviations: MABC, M. abscessus complex; MAC, M. avium complex; IQR, interquartile range.